Almac to host inaugural workshop for US biopharma companies
Consultative advice and services for US companies looking to launch drug products onto the European market
Almac is hosting its inaugural European Product Launch workshop in Boston, Massachusetts on 17 May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to assist US companies to successfully launch drug products onto the European market.
The workshop will provide US companies with important market and regulatory framework knowledge, while guiding them through the European product launch process right through from submitting an MAA to final distribution of drug products to end-users.
Attendees will also learn from the real life experiences of three of Almac's many US clients who have successfully launched drug products into the European marketplace including: Eisai Inc, Millennium: The Takeda Oncology Company and The Medicines Company.
'This workshop provides a significant opportunity for US companies to learn first hand of the processes of launching product into Europe, as many companies based outside the EU find the European regulatory and quality framework complex,' said Ian Markwell, VP of Quality for Almac's Pharma Services business unit.
Trudy Burke, Senior Director, Baltimore & Gliadel Operations, Eisai Inc and one of the key presenters at the workshop remarked: 'I am delighted to share my experience of partnering with Almac, while helping to advise US companies on the challenges of launching a high value, temperature-sensitive product in Europe.'
Further details of this workshop can be found at almaceuproductlaunch.eventbrite.com or by contacting Tania Davis directly.
